Our team discovered SARS-CoV-2 RNA in platelets (Zaid et al., Circ Res 2020) and their hyperactivation in COVID-19. This project investigates platelets as immune mediators in Long COVID, aiming to:

1. Identify platelet-specific biomarkers

2. Characterize their inflammatory signature

3. Develop therapeutic strategies

Peer-reviewed evidence confirms platelet dysfunction persists post-COVID. Platelets interact with immune cells via P-selectin/CD40L, suggesting unappreciated immunoregulatory roles. 30-60% of COVID survivors develop Long COVID. No targeted treatments exist for thrombotic complications. Our approach could benefit 100M+ patients globally.